NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis $29.00 -2.00 (-6.45%) Closing price 04:00 PM EasternExtended Trading$29.04 +0.04 (+0.14%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Quince Therapeutics Stock (NASDAQ:QNCX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quince Therapeutics alerts:Sign Up Key Stats Today's Range$26.90▼$31.2050-Day Range$17.85▼$34.5752-Week Range$15.10▼$909.98Volume40,769 shsAverage Volume18,949 shsMarket Capitalization$29.58 millionP/E RatioN/ADividend YieldN/APrice Target$206.71Consensus RatingModerate Buy Company Overview Quince Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds. Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T). A-T is a rare inherited disorder that can cause progressive neurological impairment, immune-system dysfunction and other serious complications. The company has also evaluated its delivery technology for potential applications in additional rare diseases. The company was formerly known as Cortexyme, Inc. and adopted the Quince Therapeutics name as it shifted its strategic focus toward rare-disease programs following its combination with EryDel. Quince is headquartered in the United States and conducts biotechnology research and clinical development intended to support regulatory approval and commercialization in relevant international markets.AI Generated. May Contain Errors. Read More Quince Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreQNCX MarketRank™: Quince Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 273rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingQuince Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 2 strong buy ratings, 6 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialQuince Therapeutics has a consensus price target of $206.71, representing about 612.8% upside from its current price of $29.00.Amount of Analyst CoverageQuince Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quince Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quince Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quince Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Quince Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.24% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quince Therapeutics has recently decreased by 11.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuince Therapeutics does not currently pay a dividend.Dividend GrowthQuince Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.68 News SentimentQuince Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for QNCX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quince Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.60% of the stock of Quince Therapeutics is held by insiders.Percentage Held by Institutions30.75% of the stock of Quince Therapeutics is held by institutions.Read more about Quince Therapeutics' insider trading history. Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Stock News HeadlinesQuince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript49 minutes ago | seekingalpha.comQuince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Rodman & RenshawSeptember 27 at 1:48 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 28 at 1:00 AM | Porter & Company (Ad)Rodman & Renshaw initiates coverage of Quince Therapeutics with a buySeptember 24, 2026 | msn.comQuince Therapeutics (NASDAQ:QNCX) Stock Rating Upgraded by Citizens JmpSeptember 24, 2026 | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Shares Up 9.1% - Should You Buy?September 20, 2026 | americanbankingnews.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 19, 2026 | americanbankingnews.comQuince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on ...September 17, 2026 | finance.yahoo.comSee More Headlines QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed this year? Quince Therapeutics' stock was trading at $670.00 at the beginning of the year. Since then, QNCX stock has decreased by 95.7% and is now trading at $29.00. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) announced its quarterly earnings results on Friday, August, 14th. The company reported ($12.31) EPS for the quarter, topping analysts' consensus estimates of ($28.02) by $15.71. When did Quince Therapeutics' stock split? Quince Therapeutics shares reverse split on the morning of Tuesday, June 30th 2026.The 1-20 reverse split was announced on Friday, June 26th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Quince Therapeutics IPO? Quince Therapeutics (QNCX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,412,000 shares at $16.00-$18.00 per share. Who are Quince Therapeutics' major shareholders? Top institutional investors of Quince Therapeutics include BlackRock Inc. (0.17%). Insiders that own company stock include David Lamond, Dirk Thye, Brendan Hannah and Charles S Ryan. View institutional ownership trends. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quince Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include PayPal (PYPL), SoFi Technologies (SOFI), TherapeuticsMD (TXMD), Achilles Therapeutics (ACHL), Agile Therapeutics (AGRX) and Aytu BioPharma (AYTU). Company Calendar Last Earnings8/14/2026Today9/28/2026KOL event9/28/2026EGM 202610/06/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 QNCX's financial health is in the Green zone, according to TradeSmith. QNCX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QNCX Previous SymbolNASDAQ:CRTX CIK1662774 Webwww.quincetx.com Phone(415) 910-5717FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Price Target for Quince Therapeutics$206.71 High Price Target$1,000.00 Low Price Target$68.00 Potential Upside/Downside+612.8%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($156.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.98 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-133.84% Debt Debt-to-Equity RatioN/A Current Ratio14.52 Quick Ratio14.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($128.18) per share Price / Book-0.23Miscellaneous Outstanding Shares1,020,000Free Float960,000Market Cap$29.58 million OptionableOptionable Beta1.31 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:QNCX) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
